Immediate Impact
2 from Science/Nature 63 standout
Citing Papers
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
2025 Standout
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
2023 Standout
Works of L.J.A.M. Jacobs being referenced
A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| L.J.A.M. Jacobs | 121 | 82 | 85 | 11 | 292 | |
| Katriina Parto | 50 | 100 | 59 | 13 | 290 | |
| Amber Hildreth | 97 | 33 | 32 | 10 | 316 | |
| Beth Vogel | 163 | 97 | 65 | 9 | 328 | |
| Masato Senoo | 119 | 23 | 20 | 11 | 298 | |
| Kirsten M. Niles | 144 | 83 | 13 | 14 | 281 | |
| Wendy Benson | 101 | 37 | 39 | 10 | 327 | |
| M. Molho | 42 | 20 | 29 | 15 | 298 | |
| M.P.A. Geurds | 161 | 27 | 14 | 10 | 334 | |
| Jane MacLean | 87 | 20 | 45 | 11 | 201 | |
| PH Chen | 92 | 12 | 35 | 14 | 327 |
All Works
Loading papers...